M&A / Deals Avalyn seeks public debut to support new lung drug formulations BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.M&A / DealsRespiratoryRead full story pharminent April 24, 2026 (Last updated: April 25, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. M&A / DealsRespiratoryRead full story Post navigation Previous: Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer ChannelsNext: Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer Related Stories M&A / Deals Arna Pharma and Slate Run complete JV for new US company pharminent May 15, 2026 M&A / Deals Anthropic joins Gates Foundation on $200m health AI pledge pharminent May 15, 2026 M&A / Deals Degron adds $40M to series A, supporting immunology plans for molecular glue platform pharminent May 14, 2026
